email article Adding radiation therapy to standard treatment improved failure-free survival (FFS) and overall survival for prostate cancer patients with only a few bone metastases, an exploratory analysis of the multi-arm, multi-stage STAMPEDE trial found. Among the nearly 2,000 men in the study, adding radiation to mostly androgen deprivation therapy (ADT) improved both FFS (HR 0.57, 95% CI 0.47-0.70) and overall survival (HR 0.62, 95% CI 0.46-0.83) in those with only non-regional lymph node metastasis or with fewer than three bone lesions and no visceral metastases, reported Noel Clarke, MBBS, of the Christie NHS Foundation Trust in Manchester, England, and colleagues. Patients either with visceral metastasis or four or more bone lesions still had improved FFS (HR 0.87, 95% CI 0.76-0.99,